Narrative Literature Review Guided Approach of Inhaled Corticosteroid de-escalation in Chronic Obstructive Pulmonary Disease

1. Global initiative for chronic obstructive lung disease (GOLD) 2020 report. Available at: https://goldcopd.org/gold-reports/ Accessed April 28, 2020.
Google Scholar2. Centers for disease control and progression. COPD costs. Available at: https://www.cdc.gov/copd/infographics/copd-costs.html Accessed April 28, 2020.
Google Scholar3. Miravitlles, M, Cosío, BG, Arnedillo, A, et al. A proposal for the withdrawal of inhaled corticosteroids in the clinical practice of chronic obstructive pulmonary disease. Respir Res. 2017;18:198. doi:10.1186/s12931-017-0682-y.
Google Scholar | Crossref | Medline Izquierdo, JL, Martín, A, de Lucas, P, Rodriguez-Gonazlez-Moro, JM, Almonacid, C, Paravisini, A. Misdiagnosis of patients receiving inhaled therapies in primary care. Int J Chronic Obstr Pulm Dis 2010;5:241-249. doi:10.2147/copd.s11123.
Google Scholar | Crossref | Medline5. Reddel, HK, Valenti, L, Easton, KL, Gordon, J, Bayram, C, Miller, GC. Assessment and management of asthma and chronic obstructive pulmonary disease in Australian general practice. Aust Fam Physician. 2017;46(6):413-419.
Google Scholar | Medline6. Barrecheguren, M, Monteagudo, M, Ferrer, J, et al. Treatment patterns in COPD patients newly diagnosed in primary care. A population-based study. Respir Med. 2016;111:47-53. doi:10.1016/j.rmed.2015.12.004.
Google Scholar | Crossref | Medline7. Price, D, West, D, Brusselle, G, et al. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns. Int J Chronic Obstr Pulm Dis. 2014;9:889-904. doi:10.2147/COPD.S62750.
Google Scholar | Crossref | Medline | ISI8. Burgel, P-R, Deslée, G, Jebrak, G, et al. Real-life use of inhaled corticosteroids in COPD patients versus the GOLD proposals: a paradigm shift in GOLD 2011? Eur Respir J. 2014;43(4):1201-1203. doi:10.1183/09031936.00162313.
Google Scholar | Crossref | Medline9. Vestbo, J, Hurd, SS, Rodriguez-Roisin, R. The 2011 revision of the global strategy for the diagnosis, management and prevention of COPD (GOLD) - why and what? The Clinical Respiratory Journal. 2012;6(4):208-214. doi:10.1111/crj.12002.
Google Scholar | Crossref | Medline10. Global initiative for chronic obstructive lung disease (GOLD) 2017 report. Available at: https://goldcopd.org Accessed June 9, 2020.
Google Scholar11. Nannini, LJ, Lasserson, TJ, Poole, P. Combined corticosteroid and long-acting beta2 -agonist in one inhaler versus long-acting beta2 -agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;12(9):2012CD006829. doi:10.1002/14651858.CD006829.pub2.
Google Scholar | Crossref12. Griffith, MF, Feemster, LC, Zeliadt, SB, et al. Overuse and misuse of inhaled corticosteroids among veterans with COPD: a cross-sectional study evaluating targets for de-implementation. J Gen Intern Med. 2020;35(3):679-686. doi:10.1007/s11606-019-05461-1.
Google Scholar | Crossref | Medline13. Vogelmeier, CF, Criner, GJ, Martinez, FJ, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive lung disease 2017 report. GOLD executive summary. Am J Respir Crit Care Med. 2017;195(5):557-582. doi:10.1164/rccm.201701-0218PP.
Google Scholar | Crossref | Medline | ISI14. Ernst, P, Saad, N, Suissa, S. Inhaled corticosteroids in COPD: the clinical evidence. Eur Respir J. 2015;45:525-537. doi:10.1183/09031936.00128914.
Google Scholar | Crossref | Medline | ISI15. Janson, C, Stratelis, G, Miller-Larsson, A, Harrison, T, Larsson, K. Scientific rationale for the possible inhaled corticosteroid intraclass difference in the risk of pneumonia in COPD. Int J Chronic Obstr Pulm Dis. 2017;12:3055-3064.
Google Scholar | Crossref | Medline16. Calverley, PMA, Anderson, JA, Celli, B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789. doi:10.1056/NEJMoa063070.
Google Scholar | Crossref | Medline | ISI17. Singh, S, Loke, YK. Risk of pneumonia associated with long-term use of inhaled corticosteroids in chronic obstructive pulmonary disease: a critical review and update. Curr Opin Pulm Med. 2010;16(2):118-122. doi:10.1097/MCP.0b013e328334c085.
Google Scholar | Crossref | Medline18. Suissa, S, Patenaude, V, Lapi, F, Ernst, P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68:1029-1036. doi:10.1136/thoraxjnl-2012-202872.
Google Scholar | Crossref | Medline | ISI19. Suissa, S, Kezouh, A, Ernst, P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med. 2010;123(11):1001-1006. doi:10.1016/j.amjmed.2010.06.019.
Google Scholar | Crossref | Medline20. Price, DB, Voorham, J, Brusselle, G, et al. Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study. Npj Primary Care Respiratory Medicine. 2019;29(38). doi:10.1038/s41533-019-0150-x.
Google Scholar | Crossref21. Burge, PS, Calverly, PM, Jones, PW, Spencer, S, Anderson, JA, Maslen, TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320(7245):1297-1303. doi:10.1136/bmj.320.7245.1297.
Google Scholar | Crossref | Medline22. Schermer, TRJ, Hendriks, AJC, Chavannes, NH, et al. Probability and determinants of relapse after discontinuation of inhaled corticosteroids in patients with COPD treated in general practice. Prim Care Respir J. 2004;13(10):48-55. doi:10.1016/j.pcrj.2003.11.005.
Google Scholar | Crossref | Medline23. O'BRIEN, A, Russo-Magno, P, Karki, A, et al. Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med. 2001;164(3):365-371. doi:10.1164/ajrccm.164.3.2002052.
Google Scholar | Crossref | Medline24. Nadeem, NJ, Taylor, SJ, Eldridge, SM. Withdrawal of inhaled corticosteroids in individuals with COPD - a systematic review and comment on trial methodology. Respir Res. 2011;12(107). doi:10.1186/1465-9921-12-107.
Google Scholar | Crossref | Medline25. Van der Valk, P, Monninkhof, E, van der Palen, J, Zielhuis, G, van Herwaarden, C. Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166(10):1358-1363. doi:10.1164/rccm.200206-512OC.
Google Scholar | Crossref | Medline26. Wouters, EFM, Postma, DS, Fokkens, B, et al.. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 2005;60:480-487. doi:10.1136/thx.2004.034280.
Google Scholar | Crossref | Medline | ISI27. Calzetta, L, Matera, MG, Braido, F, et al. Withdrawal of inhaled corticosteroids in COPD: A meta-analysis. Pulm Pharmacol Therapeut. 2017;45:148-158. doi:10.1016/j.pupt.2017.06.002.
Google Scholar | Crossref | Medline28. Rossi, A, Guerriero, M, Corrado, A, OPTIMO/AIPO Study Group. Withdrawal of inhaled corticosteroids can be safe in COPD patients at low risk of exacerbation: a real-life study on the appropriateness of treatment in moderate COPD patients (OPTIMO). Respir Res. 2014;15:77. doi:10.1186/1465-9921-15-77.
Google Scholar | Crossref | Medline | ISI29. Vogelmeier, C, Worth, H, Buhl, R, et al. “Real-life” inhaled corticosteroid withdrawal in COPD: a subgroup analysis of DACCORD. Int J Chronic Obstr Pulm Dis. 2017;12:487-494. doi:10.2147/COPD.S125616.
Google Scholar | Crossref | Medline30. Sannigrahi, S, Wang, C, Zhou, X, et al. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD. Int J Chronic Obstr Pulm Dis. 2015;10:1015-1026. doi:10.2147/COPD.S84436.
Google Scholar | Crossref | Medline31. Vogelmeier, CF, Gaga, M, Gaga, M, et al. Efficacy and safety of direct switch to indacaterol/glycopyrronium in patients with moderate COPD: the CRYSTAL open-label randomised trial. Respir Res. 2017;18(18):140. doi:10.1186/s12931-017-0622-x.
Google Scholar | Crossref | Medline32. Lipson, DA, Barnhart, F, Brealey, N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671-1680. doi:10.1056/NEJMoa1713901.
Google Scholar | Crossref | Medline33. Rabe, KF, Martinez, FJ, Ferguson, GT, et al. Triple inhaled therapy at two glucocorticoid doses in moderate-to-very-severe COPD. N Engl J Med. 2020;383:35-48. doi:10.1056/NEJMoa1916046.
Google Scholar | Crossref | Medline34. Global Initiative for Asthma . Global strategy for asthma management and prevention. 2020. Available at: www.ginaasthma.org www.ginaasthma.org Accessed September 7, 2020.
Google Scholar35. Lacoste, J, Bousquet, J, Chanez, P, et al. Eosinophilic and neutrophilic inflammation in asthma, chronic bronchitis, and chronic obstructive pulmonary disease. J Allergy Clin Immunol. 1993;92(4):537-548. doi:10.1016/0091-6749(93)90078-t.
Google Scholar | Crossref | Medline36. Bafadhel, M, McKenna, S, Terry, S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(1):48-55. doi:10.1164/rccm.201108-1553OC.
Google Scholar | Crossref | Medline37. Watz, H, Tetzlaff, K, Wouters, EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. The Lancet Respiratory Medicine. 2016;4(5):390-398. doi:10.1016/S2213-2600(16)00100-4.
Google Scholar | Crossref | Medline38. Pascoe, S, Locantore, N, Dransfield, MT, Barnes, NC, Pavord, ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. The Lancet Respiratory Medicine. 2015;3:435-442. doi:10.1016/S2213-2600(15)00106-X.
Google Scholar | Crossref | Medline39. Saha, S, Brightling, CE. Eosinophilic airway inflammation in COPD. International Journal of COPD. 2006;1(1):39-47. doi:10.2147/copd.2006.1.1.39.
Google Scholar | Crossref40. Siddiqui, SH, Guasconi, A, Vestbo, J, et al. Blood eosinophils: a biomarker of response to extrafine beclomethasone/formoterol in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(4):523-525. doi:10.1164/rccm.201502-0235LE.
Google Scholar | Crossref | Medline41. Chapman, KR, Hurst, JR, Frent, S-M, et al. Long-term triple therapy de-escalation to indacaterol/glycopyrronium in patients with chronic obstructive pulmonary disease (SUNSET): a randomized, double-blind, triple-dummy clinical trial. Am J Respir Crit Care Med. 2018;198(3):329-339. doi:10.1164/rccm.201803-0405OC.
Google Scholar | Crossref | Medline42. Cazzola, M, Rogliani, P, Calzetta, L, Matera, MG. Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis. Eur Respir J. 2018 Dec 13;52(6):1801586. doi:10.1183/13993003.01586-2018.
Google Scholar | Crossref | Medline43. Cheng, S-L . Blood eosinophils and inhaled corticosteroids in patients with COPD: systematic review and meta-analysis. Int J Chronic Obstr Pulm Dis. 2018;Volume 13(13):2775-2784. doi:10.2147/COPD.S175017.
Google Scholar | Crossref44. Stockley, RA, Halpin, DMG, Celli, BR, Singh, D. Chronic obstructive pulmonary disease biomarkers and their interpretation. Am J Respir Crit Care Med. 2019;199(10):1195-1204. doi:10.1164/rccm/201810-1860SO.
Google Scholar | Crossref |

留言 (0)

沒有登入
gif